Hartmut Goldschmidt

1993–2026 年に発表

288
論文数
53,071
被引用数
109
h 指数
269
i10 指数

被引用数

Hartmut Goldschmidt の年別被引用数1948 年: 被引用 1 件1984 年: 被引用 1 件1988 年: 被引用 3 件1990 年: 被引用 4 件1993 年: 被引用 3 件1994 年: 被引用 8 件1995 年: 被引用 14 件1996 年: 被引用 9 件1997 年: 被引用 14 件1998 年: 被引用 14 件1999 年: 被引用 6 件2000 年: 被引用 21 件2001 年: 被引用 8 件2002 年: 被引用 10 件2003 年: 被引用 22 件2004 年: 被引用 30 件2005 年: 被引用 41 件2006 年: 被引用 93 件2007 年: 被引用 123 件2008 年: 被引用 141 件2009 年: 被引用 195 件2010 年: 被引用 174 件2011 年: 被引用 182 件2012 年: 被引用 177 件2013 年: 被引用 236 件2014 年: 被引用 244 件2015 年: 被引用 282 件2016 年: 被引用 321 件2017 年: 被引用 419 件2018 年: 被引用 364 件2019 年: 被引用 1,655 件2020 年: 被引用 2,004 件2021 年: 被引用 2,031 件2022 年: 被引用 1,747 件2023 年: 被引用 1,268 件2024 年: 被引用 2,447 件2025 年: 被引用 1,075 件2026 年: 被引用 36 件1949〜1983 年は被引用が無いため表示していません1985〜1987 年は被引用が無いため表示していません1989 年は被引用が無いため表示していません1991〜1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,689 件、この内訳の 25.2%ドイツ: 引用元論文 1,050 件、この内訳の 7.2%中国: 引用元論文 1,012 件、この内訳の 6.9%イタリア: 引用元論文 914 件、この内訳の 6.2%イギリス: 引用元論文 867 件、この内訳の 5.9%フランス: 引用元論文 778 件、この内訳の 5.3%スペイン: 引用元論文 697 件、この内訳の 4.7%オランダ: 引用元論文 504 件、この内訳の 3.4%カナダ: 引用元論文 461 件、この内訳の 3.1%ギリシャ: 引用元論文 406 件、この内訳の 2.8%オーストラリア: 引用元論文 362 件、この内訳の 2.5%ベルギー: 引用元論文 320 件、この内訳の 2.2%
0%25.2%その他 24.6%

分野

  • Medicine77%
  • Biochemistry, Genetics and Molecular Biology17.3%
  • Immunology and Microbiology3%
  • Computer Science0.5%
  • Engineering0.4%
  • Health Professions0.4%
  • その他1.4%

トピック

  • Multiple Myeloma Research and Treatments18.9%
  • Protein Degradation and Inhibitors7.8%
  • CAR-T cell therapy research5.7%
  • Peptidase Inhibition and Analysis4.4%
  • Ubiquitin and proteasome pathways2.8%
  • Cancer Treatment and Pharmacology2.7%
  • その他57.7%

共著者

全論文

検索で開く
  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 2,424

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau - The Lancet Oncology 2016 被引用: 2,995

  3. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 被引用: 4,869

  4. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Moreau - Journal of Clinical Oncology 2015 被引用: 2,178

  5. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    著者: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 820

  6. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

    著者: , , , , , , , , , , , , , , , , , , , - Cancer Cell 2023 被引用: 247

  7. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld - Journal of Clinical Oncology 2022 被引用: 407

  8. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 被引用: 240

  9. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 987

  10. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 363

  11. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Leukemia 2018 被引用: 453

  12. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 1,434

  13. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 被引用: 327

  14. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 141

  15. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 被引用: 496

  16. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Blood 2018 被引用: 495

  17. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 被引用: 275

  18. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Hoffmann, Marc S. Raab, Hans Salwender, Katja Weisel, Katja C Weisel, Anne M Asemissen, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Uta Bertsch, Britta Besemer, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Jan Dürig, Roland Fenk, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Thomas Geer, Deniz Gezer, Hartmut Goldschmidt, Hartmut Goldschmidt, Martin Görner, Ullrich Graeven, Jochen Grassinger, Mathias Hänel, Bernhard Heilmeier, Michael Heinsch, Gerhard Held, Martin Hoffmann, Tobias A W Holderried, Olaf Hopfer, Stefanie Huhn, Peter Immenschuh, Dominic Kaddu-Mulindwa, Cyrus Khandanpour, Maika Klaiber-Hakimi, Martine Klausmann, Stefan Klein, Wolfgang Knauf, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Katharina Kriegsmann, Martin Kropff, Paul La Rosée, Steffen P Luntz, Rolf Mahlberg, Elias K Mai, Christoph Mann, Uwe Martens, Ivana von Metzler, Martin Müller, Markus Munder, Michael Neise, Eva Nievergall, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Marc S Raab, Mohammed R Rafiyan, Peter Reimer, Armin Riecke ほか 27 名 - The Lancet Haematology 2022 被引用: 154

  19. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , - Blood 2016 被引用: 929

  20. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics

    著者: , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 133

  21. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc S. Raab, Fritz Van Rhee, Saad Z. Usmani, Kenneth H. Shain, Niels Weinhold, Gareth J. Morgan, Ola Landgren - Journal of Clinical Oncology 2024 被引用: 119

  22. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Achilleas Anagnostopoulos, Larry D. Anderson, Pekka Anttila, Carla Araujo, Carlos Arce‐Lara, Yıldız Aydın, Supratik Basu, Ramakrishna Battini, Thaddeus Beeker, Lotfi Benboubker, Dina Ben‐Yehuda, Joan Bladé, Igor Wolfgang Blau, Ralph V. Boccia, Lillian Burke, Peter D. Byeff, Nicola Cascavilla, Michèle Cavo, Andrew Chantry, Yen Charles, Arvind Chaudhry, Alessandro Corso, Mark Coyne, Felipe de Arriba, Sosana Delimpasi, Pierre Desjardins, Binod Dhakal, Paolo Di Bartolomeo, Francesco Di Raimondo, Jan Dürig, Monika Engelhardt, Martine Escoffre‐Barbe, Graça Esteves, Max Flogegård, Nashat Gabrail, Barbara Gamberi, Mitchell Garrison, Julie Gay, Heinz Gisslinger, Hartmut Goldschmidt, Cristina Gonçalves, Laurent Gressot, Sebastian Grosicki, Wahid T. Hanna, Patrick Hayden, Maria Manuela Henriques Bernardo, Róbert Hermann, Viran Holden, Kirsti Honkalehto, Marianne Huben, John Huffman, Hannah Hunter, Marek Hus, Madan Jagasia, Sundar Jagganath, Murali Janakiram, Ishmael Jaiyesimi, Matthew Jenner, Cristina João, Peter Johnson, Artur Jurcyszyn, Sevgi Kalayoğlu Beşışık, Suman Kambhampati, Abraham S. Kanate, Ìhsan Karadoǧan, Ali Khojasteh, Dean Kirkel, Mieczysław Komarnicki, Maria‐Theresa Krauth, Phillip Kuriakose ほか 65 名 - The Lancet Oncology 2019 被引用: 385

  23. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 243

  24. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 被引用: 268